Author details

Full Name

Robert Hirten

Affiliation

ORCID

Career Start Year

2014

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37143859	A machine learning approach to determine resilience utilizing wearable device data: analysis of an observational cohort.	JAMIA Open	2023
36149668	Impact of Care in an Interdisciplinary Inflammatory Bowel Disease Specialty Clinic on Outcomes in Patients Insured with Medicaid.	J Clin Gastroenterol	2023
34825393	Autoimmune conditions in the World Trade Center general responder cohort: A nested case-control and standardized incidence ratio analysis.	Am J Ind Med	2022
35762696	The future of telemedicine and wearable technology in IBD.	Current Opinion in Gastroenterology	2022
36348637	COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study.	Therap Adv Gastroenterol	2022
35677186	Evaluation of a machine learning approach utilizing wearable data for prediction of SARS-CoV-2 infection in healthcare workers.	JAMIA Open	2022
33039584	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.	Clin Gastroenterol Hepatol	2022
34791254	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease.	Inflamm Bowel Dis	2022
34379602	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data.	J Med Internet Res	2021
33529156	Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study.	J Med Internet Res	2021
33527691	Autoimmune and Chronic Inflammatory Disease Patients with COVID-19.	ACR Open Rheumatol	2021
33502898	New Therapeutics for Ulcerative Colitis.	Annu Rev Med	2021
32705439	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study.	Dig Dis Sci	2021
33248096	Reply.	Clinical Gastroenterology and Hepatology	2021
32629130	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.	Clin Gastroenterol Hepatol	2021
33068786	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.	Clin Gastroenterol Hepatol	2021
32835842	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population.	Clin Gastroenterol Hepatol	2021
33382065	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare.	Inflamm Bowel Dis	2021
34791290	Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System.	Inflamm Bowel Dis	2021
30910602	Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.	Clin Gastroenterol Hepatol	2020
31696976	Review article: bacteriophages in gastroenterology-from biology to clinical applications.	Aliment Pharmacol Ther	2020
31639193	Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence.	Inflamm Bowel Dis	2020
32062041	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.	Clin Gastroenterol Hepatol	2020
32058070	Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.	Clin Immunol	2020
31887444	A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.	Clin Gastroenterol Hepatol	2020
32656800	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.	Aliment Pharmacol Ther	2020
32584190	Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic study.	Scand J Gastroenterol	2020
30706608	Surgical solutions for refractory J-pouch inlet obstruction.	Colorectal Disease	2019
31579976	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis.	Aliment Pharmacol Ther	2019
30268561	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.	Clin Gastroenterol Hepatol	2019
30019143	Diffusion and perfusion MRI quantification in ileal Crohn's disease.	Eur Radiol	2019
30625408	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.	Clin Gastroenterol Hepatol	2019
30320666	Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease.	Journal of Pediatric Gastroenterology and Nutrition	2019
30852592	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.	Inflamm Bowel Dis	2019
30848194	Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?	Curr Pharm Des	2019
30782323	Reply.	Clin Gastroenterol Hepatol	2019
30666957	Gut microbiota density influences host physiology and is shaped by host and microbial factors.	Elife	2019
31050734	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.	Inflamm Bowel Dis	2019
31512019	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study.	Int J Colorectal Dis	2019
29788240	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.	Inflamm Bowel Dis	2018
30390030	Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.	Am J Gastroenterol	2018
29946178	Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.	Am J Gastroenterol	2018
29857091	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn'sÂ Disease.	Gastroenterology	2018
29141957	Adherent-invasive <i>Escherichia coli</i> in inflammatory bowel disease.	Gut	2018
29528400	The Management of Intestinal Penetrating Crohn's Disease.	Inflamm Bowel Dis	2018
29481970	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.	Clin Gastroenterol Hepatol	2018
29477303	Identification of volumetric laser endomicroscopy features of colon polyps with histologic correlation.	Gastrointest Endosc	2018
29792734	Clinical updates on perianal fistulas in Crohn's disease.	Expert Rev Gastroenterol Hepatol	2018
28110094	Colonic Pseudopolyps Resulting in Iron Deficiency Anemia.	Clin Gastroenterol Hepatol	2017
28410893	Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease.	Clin Gastroenterol Hepatol	2017